Merck KGaA has developed a vision of a SMARTfacturing ecosystem. [Merck KGaA/Darmstadt, Germany] Merck KGaA has developed a SMARTfacturing vision ecosystem, which is a structured, multi-layered ...

Merck KGaA operates in three key segments: healthcare, life science, and electronics. Over the past decade, strategic acquisitions and divestments have strengthened its position in these ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €190.00. See what stocks are receiving Strong Buy ...

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price ...

How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck KGaA is doubling down on AI through a new collaboration agreement with tech firm Iktos, using its generative modelling technology to speed up the discovery and design of promising new compounds.

Germany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China. Darmstadt-based Merck’s strategic tie-up with the China-based multinational tech ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

today announced that it has entered into a five-year global distribution and collaboration agreement (the “Agreement”) with the Life Science business of Merck KGaA , Darmstadt, Germany ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...